We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > OC-01

News List

The Pharmaceutical Company Licenses in Two New Drugs for Dry Eye Disease with over 200 Million US Dollars PharmaSources/Yefenghong
August 25, 2021
On August 5, Oyster Point Pharma, Inc. revealed on its official website that it has reached a cooperation agreement with Ji Xing Pharmaceuticals, which will develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for patients.
Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors firstwordpharma
August 03, 2021
Oyster Point Pharma, Inc. (Nasdaq: OYST) today announced the appointment of a new Director and Chairperson to its Board of Directors.
Oyster Point raises $93m in financing round to fund DED pipeline pharmaceutical-technology
February 28, 2019
Princeton-based clinical stage pharma company Oyster Point has announced it has raised $93m in a Series B funding round. The investment will be used to support the development of its Dry Eye Disease (DED) portfolio....